The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help get some people back to work.

In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a trial assessing weight loss jabs' effects on employment, productivity, and heal